SCHEMBL4621563

SCHEMBL4621563

CCCCC[C@@]1(O[SiH3])[C@H](O)[C@@H](CO)O[C@@]1(F)n1ccc(N)nc1=O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE3A Q14432 3/20 0.44
PDE4D Q08499 1/20 0.44
SLC29A1 Q99808 1/20 0.44
LMNA P02545 4/20 0.39
THRB P10828 1/20 0.39
MTOR P42345 1/20 0.39
MDM2 Q00987 1/20 0.39
NCOA1 Q15788 1/20 0.39
NCOA3 Q9Y6Q9 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.37
POLA1 P09884 1/20 0.34
FGFR1 P11362 4/20 0.33
CACNA1F O60840 2/20 0.32
ALB P02768 2/20 0.32
MAPT P10636 2/20 0.32
CACNA1D Q01668 2/20 0.32
CACNA1S Q13698 2/20 0.32
CACNA1C Q13936 2/20 0.32
POLB P06746 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27712544 0.85 PDE3A (0.46) PDE3APDE4DSLC29A1LMNATHRB
SCHEMBL3474446 0.78 PDE3A (0.53) PDE3APDE4DSLC29A1LMNATHRB
SCHEMBL28569717 0.77 PDE3A (0.53) PDE3APDE4DSLC29A1LMNATHRB
SCHEMBL27999217 0.77 PDE3A (0.52) PDE3APDE4DSLC29A1LMNATHRB
Methyl Alcohol SCHEMBL27751480 0.77 PDE3A (0.52) PDE3APDE4DSLC29A1LMNATHRB
Hydrochloric Acid SCHEMBL3345909 0.77 PDE3A (0.52) PDE3APDE4DSLC29A1LMNATHRB
SCHEMBL6060585 0.77 LMNA (0.45) PDE3APDE4DSLC29A1LMNATHRB
SCHEMBL25407209 0.76 LMNA (0.44) PDE3APDE4DSLC29A1LMNATHRB
SCHEMBL29597277 0.76 PDE3A (0.44) PDE3APDE4DSLC29A1LMNATHRB
SCHEMBL31190163 0.76 PDE4D (0.42) PDE3APDE4DSLC29A1LMNATHRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101128472-B Process for fluorocytidine derivatives HOFFMANN LA ROCHE 2012-03-14 CN disclosed
EP-1706414-B1 PROCESS FOR FLUOROCYTIDINE DERIVATIVES HOFFMANN LA ROCHE (CH) 2008-07-23 EP disclosed
US-7365188-B2 Process for producing N4-Acyl-5′-deoxy-5-fluorocytidine ROCHE COLORADO CORPORATION (US) 2008-04-29 US disclosed
CN-101128472-A Process for fluorocytidine derivatives ROCHE COLORADO CORP (CH) 2008-02-20 CN disclosed
EP-1706414-A2 PROCESS FOR FLUOROCYTIDINE DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 2006-10-04 EP disclosed
WO-2005063786-A2 PROCESS FOR FLUOROCYTIDINE DERIVATIVES F.HOFFMAN-LA ROCHE AG (CH) 2005-07-14 WO disclosed
US-20050137392-A1 Process for producing N4-Acyl-5'-deoxy-5-fluorocytidine ROCHE COLORADO CORPORATION (US) 2005-06-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050137392-A1 Process for producing N4-Acyl-5'-deoxy-5-fluorocytidine RNGTT, DUT, DCK PDE3A 4545/4885PDE4D 2997/4885SLC29A1 631/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.